Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing its investigational drug product, seralutinib, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib is an inhaled inhibitor designed to enhance the lives of people living with these rare diseases. The company is committed to advancing new therapies and supporting patient communities.